Chemring appoints interim CFO
Military counter-measures specialist Chemring has appointed Nigel Young as its interim Chief Financial Officer with immediate effect, replacing Paul Rayner, who will step down on July 31st.
Military counter-measures specialist Chemring has appointed Nigel Young as its interim Chief Financial Officer with immediate effect, replacing Paul Rayner, who will step down on July 31st.
59-year-old Young has considerable experience within both the defence and manufacturing industries. He was finance director of United Scientific Holdings, First Technology and Babcock International.
More recently, he was Group Finance Director of the FTSE 250 company, Morgan Crucible, until he retired in 2004. Since then Young has undertaken a number of charitable, interim and consultancy roles, including the UK Atomic Energy Authority and McBride.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Rayner, who has been Chemring's chief bean-counter since 1999. announced his decision to step down from the role back in March.
The process of selecting a permanent candidate for the role of Chief Financial Officer is ongoing, and the group will make a further announcement in due course, Chemring said.
NR
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
Energy bills to rise by 1.2% in January 2025
Energy bills are set to rise 1.2% in the New Year when the latest energy price cap comes into play, Ofgem has confirmed
By Dan McEvoy Published
-
Should you invest in Trainline?
Ticket seller Trainline offers a useful service – and good prospects for investors
By Dr Matthew Partridge Published